Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Withdrawn 2Completed 1

Sponsor Class

OTHER 4NIH 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Neoplasms, Plasma Cell 3Multiple Myeloma 3Polycystic Ovary Syndrome 1Obesity 1

Interventions

Melphalan 20Cyclophosphamide 17Dexamethasone 14Peripheral Blood Stem Cell Transplantation 12Filgrastim 9sargramostim 8fludarabine phosphate 7Interferon-alpha 7Busulfan 7Bortezomib 7Vincristine 6Thalidomide 6Prednisone 6Doxorubicin 5Antilymphocyte Serum 5Radiotherapy 4Cyclosporine 4Mycophenolic Acid 3Methylprednisolone 3Idarubicin 3Etoposide 3Drug Therapy 3Ascorbic Acid 3Arsenic Trioxide 3Rituximab 2Methotrexate 2Interleukin-12 Subunit p35 2Ifosfamide 2Cytarabine 2Carmustine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NIH × Neoplasms, Plasma Cell × Ascorbic Acid × Clear all
NCT00317811 2013-11-06

Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Completed
35 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00085345 2013-07-10

Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00112879 2013-07-10

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡